Fenazopiridina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fenazopiridina" in Italian language version.

refsWebsite

Global rank Italian rank

12nih.gov

4^th place

9^th place

2oadoi.org

799^th place

22^nd place

2doi.org

2^nd place

7^th place

1web.archive.org

1^st place

doi.org

dx.doi.org

TA. Kermani, SV. Pislaru; TG. Osborn, Acrocyanosis from phenazopyridine-induced sulfhemoglobinemia mistaken for Raynaud phenomenon., in J Clin Rheumatol, vol. 15, n. 3, aprile 2009, pp. 127-9, DOI:10.1097/RHU.0b013e31819db6db, PMID 19300288.
AS. Gopalachar, VL. Bowie; P. Bharadwaj, Phenazopyridine-induced sulfhemoglobinemia., in Ann Pharmacother, vol. 39, n. 6, giugno 2005, pp. 1128-30, DOI:10.1345/aph.1E557, PMID 15886294.

nih.gov

ncbi.nlm.nih.gov

BH. Thomas, LW. Whitehouse; G. Solomonraj; CJ. Paul, Excretion of phenazopyridine and its metabolites in the urine of humans, rats, mice, and guinea pigs., in J Pharm Sci, vol. 79, n. 4, aprile 1990, pp. 321-5, PMID 2352143.
M. Jurima-Romet, BH. Thomas; G. Solomonraj; CJ. Paul; H. Huang, Metabolism of phenazopyridine by isolated rat hepatocytes., in Biopharm Drug Dispos, vol. 14, n. 2, marzo 1993, pp. 171-9, PMID 8453026.
G. Amit, A. Halkin, Lemon-yellow nails and long-term phenazopyridine use., in Ann Intern Med, vol. 127, n. 12, dicembre 1997, p. 1137, PMID 9412335.
M. Tishler, A. Abramov, Phenazopyridine-induced hemolytic anemia in a patient with G6PD deficiency., in Acta Haematol, vol. 70, n. 3, 1983, pp. 208-9, PMID 6410650.
E. Galun, R. Oren; M. Glikson; M. Friedlander; A. Heyman, Phenazopyridine-induced hemolytic anemia in G-6-PD deficiency., in Drug Intell Clin Pharm, vol. 21, n. 11, novembre 1987, pp. 921-2, PMID 3678069.
JE. Mercieca, MF. Clarke; ME. Phillips; JR. Curtis, Acute hemolytic anaemia due to phenazopyridine hydrochloride in G-6-PD deficient subject., in Lancet, vol. 2, n. 8297, settembre 1982, p. 564, PMID 6125724.
JE. Frank, Diagnosis and management of G6PD deficiency., in Am Fam Physician, vol. 72, n. 7, ottobre 2005, pp. 1277-82, PMID 16225031.
WH. Jeffery, AP. Zelicoff; WR. Hardy, Acquired methemoglobinemia and hemolytic anemia after usual doses of phenazopyridine., in Drug Intell Clin Pharm, vol. 16, n. 2, febbraio 1982, pp. 157-9, PMID 7075467.
JS. Daly, DE. Hultquist; DL. Rucknagel, Phenazopyridine induced methaemoglobinaemia associated with decreased activity of erythrocyte cytochrome b5 reductase., in J Med Genet, vol. 20, n. 4, agosto 1983, pp. 307-9, PMID 6620333.
SM. Halvorsen, WL. Dull, Phenazopyridine-induced sulfhemoglobinemia: inadvertent rechallenge., in Am J Med, vol. 91, n. 3, settembre 1991, pp. 315-7, PMID 1892154.
TA. Kermani, SV. Pislaru; TG. Osborn, Acrocyanosis from phenazopyridine-induced sulfhemoglobinemia mistaken for Raynaud phenomenon., in J Clin Rheumatol, vol. 15, n. 3, aprile 2009, pp. 127-9, DOI:10.1097/RHU.0b013e31819db6db, PMID 19300288.
AS. Gopalachar, VL. Bowie; P. Bharadwaj, Phenazopyridine-induced sulfhemoglobinemia., in Ann Pharmacother, vol. 39, n. 6, giugno 2005, pp. 1128-30, DOI:10.1345/aph.1E557, PMID 15886294.

oadoi.org

TA. Kermani, SV. Pislaru; TG. Osborn, Acrocyanosis from phenazopyridine-induced sulfhemoglobinemia mistaken for Raynaud phenomenon., in J Clin Rheumatol, vol. 15, n. 3, aprile 2009, pp. 127-9, DOI:10.1097/RHU.0b013e31819db6db, PMID 19300288.
AS. Gopalachar, VL. Bowie; P. Bharadwaj, Phenazopyridine-induced sulfhemoglobinemia., in Ann Pharmacother, vol. 39, n. 6, giugno 2005, pp. 1128-30, DOI:10.1345/aph.1E557, PMID 15886294.

web.archive.org

Philip M. Hanno, David Allen Burks, J. Quentin Clemens, Roger R. Dmochowski, Deborah Erickson, Mary Pat FitzGerald, John B. Forrest, Barbara Gordon, Mikel Gray, Robert Dale Mayer, Diane Newman, Leroy Nyberg Jr., Christopher K. Payne, Ursula Wesselmann, Martha M. Faraday, American Urological Association (AUA) Guideline. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome (PDF), su auanet.org, gennaio 2011. URL consultato il 23 gennaio 2013. (archiviato dall'url originale il 16 settembre 2012).